Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 246-002-7 | CAS number: 24057-28-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 2016
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes]
- Age at study initiation: approx 12-13 weeks at start of treatment
- Weight at study initiation: males 425-502 g, females 237-306 g
- Fasting period before study: no
- Housing: up to 3 animals of the same sex and dose group/cage with the exception of the mating and gestation/delivery period when they were paired or indivdually housed
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 5 days
DETAILS OF FOOD AND WATER QUALITY:
animals received ssniff SM R/M complete diet for rats and mice, Soest, Germany
animals received tap water from municipal supply.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.2 - 25.0
- Humidity (%): 29 - 64
- Air changes (per hr): 15 -20
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- - PREPARATION OF DOSING SOLUTIONS:
the test substance is very well water soluble. From the solid test material a stock solution of 741 g/l water was prepared, and further diluted.
- DIET PREPARATION
- Rate of preparation of diet (frequency):
- Mixing appropriate amounts with (Type of food):
- Storage temperature of food:
- VEHICLE
- Justification for use and choice of vehicle (if other than water):
- Concentration in vehicle: 6, 20, 60 mg/ml
- Amount of vehicle (if gavage): 5 ml/kg body weight
- Lot/batch no. (if required):
- Purity: - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- HPLC with UV detector was used to determine the concentrations in the dosing solutions at 3 occasions during the study. The concentrations determined ranged between 97% and 103% recovery of the nominal concentration.
- Duration of treatment / exposure:
- males were dosed for 28 days starting 14 days prior to mating. Females were dosed for 14 days prior to mating, during mating, gestation until day 13 post partum.
- Frequency of treatment:
- daily
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- according to guideline OECD 422 (2016)
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: at least weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: food consumption was determined
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: just before necropsy
- Anaesthetic used for blood collection: Yes pentobarbital
- Animals fasted: Yes
- How many animals: 5 per sex and dose group
- Parameters checked in table [No.?] were examined: see Table on haematology attached as background material
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: just before necropsy
- Animals fasted: Yes
- How many animals: 5 per sex and dose group
- Parameters checked in table [No.?] were examined.: see Table on clinical chemistry and urinalysis attached as background material
URINALYSIS: Yes
- Time schedule for collection of urine: just before necropsy
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Not specified
- Parameters checked in table [No.?] were examined: see Table on clinical chemistry and urinalysis attached as background material
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during the last exposure week
- Dose groups that were examined: all dose groups
- Battery of functions tested: sensory activity / grip strength / motor activity.
IMMUNOLOGY: No
- Time schedule for examinations:
- How many animals:
- Dose groups that were examined:
- Parameters checked in table [No.?] were examined.
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table)
see "pathology and histopathology investigations" attached as background material - Statistics:
- The statistical evaluation of data (labelled as † in the lists below) was performed with the program package SPSS PC+4.0 (SPSS Hungary Kft, Budapest) or SAS v9.2 (when using Provantis).
In case of the SPSS PC+4.0 program package, the heterogeneity of variance between groups was checked by Bartlett's test. Where no significant heterogeneity was detected, a one-way analysis of variance (ANOVA) was carried out. If the obtained result was significant, then Duncan's Multiple Range test was used to assess the significance of inter-group differences. Where significant heterogeneity was found, the normal distribution of data was examined by Kolmogorow-Smirnow test. In the case of non-normal distribution, the non-parametric method of Kruskal-Wallis One- Way analysis of variance was applied. If a positive result was detected, the inter-group comparisons were performed using Mann-Whitney U-test. The Chi-squared test was used for non-continuous data. - Clinical signs:
- effects observed, non-treatment-related
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- one female of the control group was preterminally euthanised the day after littering for animal welfare reasons (protrusion of the vagina). One female of the high dose group was found dead on the day of littering; the cause of death could not be determined.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, on the week after initiation of treatment, the body weight gain in the High dose was 74% below control (p<0.01) but the males fully compensated for this in the following week. During the third week the body weight gain was again below the control values (-36%, no statistical significance) and in the fourth week, the animals compensated the difference again. Although there were no statistical differences in the overall body weight gain of the High dose compared to the control, it is noted that the bodyweight gain of the animals was disturbed most probably by the test item. The body weight gain of the Mid dose males were slightly below the Control during the first three weeks, without reaching statistical significances. These minor differences in the Mid dose group were considered to have no toxicological significance. The body weight and body gain weight values of the Low dose males were comparable to the control during the whole observation period.
In the High dose females, during the first week of treatment, the mean body weight gain was near zero (many individuals lost weight) but, as for the males, the weights tended to recover after Day 7. However, the High dose remained below control throughout gestation. After parturition 5/10 dams lost weight or remained at the same weight during the first 4 days of lactation whereas 4/10 dams gained body weight (1/10 dams died on the day of parturition). Statistically significantly lower body weights were recorded from the seventh day of the gestation period until the end of the observed lactation period. Slightly lower bodyweights were recorded also in the female Mid dose group during this period, occasionally reaching statistical significance. These minor differences in the Mid dose group were considered to have no toxicological significance. The body weights of the Low dose females were comparable to the control.
see Figures and Tables on body weight attached as background material - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In males, slightly lower food consumption was recorded in the High dose group compared to the controls during the first week, reaching statistical significance. The overall intake over the whole study was similar in all groups.
The food consumption of the females showed similar patterns as the body weight changes; there were consistently significantly lower values in the High dose. After parturition, low food consumption values were recorded for 5/10 dams during the first 4 days of lactation whereas 4/10 dams had similar food consumption as the controls (1/10 dams died on the day of parturition). To a much lesser extent, during the first 3 weeks of treatment slightly lower values were also seen in Mid dose. The food consumption of the Low dose females was comparable to the control at any occasion.
see Tables on food consumption attached as background material - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Significantly lower (p<0.05) activated partial thromboplastin time (APTT) in the male High dose group and significantly lower (p<0.05 or p<0.01) prothrombin time (PTT) in the Mid and High dose male groups were recorded. Considering the individual values of the High dose, 2 of the 5 males had APPT and PPT values below the historical control range (and additionally one animal had 9.9 sec APTT value which is just below the 10.0 sec lower limit of the historical control range). In females all values were normal with clearly no treatment related trend in these parameters. There was no other supporting evidence of any changes in these animals (other clinical pathology parameters, histopathology, etc.) so the relationship between the 2 low APTT and PPT values and treatment was considered to be equivocal. Generally, slightly shorter clotting time parameters is not considered to be an adverse effect. While it is plausible that liver changes may have slightly affected these parameters, these differences are not considered to be an adverse effect of the test item.
Besides this, there were no other statistically significant values recorded in any of the dose groups compared to the control. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The following statistically significant differences were recorded in males: Significantly (p<0.05 or p<0.01) higher cholesterol concentration in the Mid and High dose groups, significantly (p<0.05 or p<0.01) higher phosphorus concentration in all dose groups, significantly (p<0.01) lower sodium concentration in the High dose group, significantly lower (p<0.05 or p<0.01) chloride concentration in all dose groups, significantly (p<0.05) higher albumin level in the Mid dose group, significantly (p<0.05) lower alkaline phosphatase concentration in the Low and Mid dose groups and significantly (p<0.05) higher bile acid concentration in the High dose group. In females all values were normal. As all these values were within the historical ranges, it was considered that there were no adverse effects of treatment at any dose level.
see Table on clinical chemistry parameters attached as background material - Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, significantly higher absolute and relative kidney weights were recorded in the Mid and High dose groups. The kidney weights in the female dose groups were comparable to the control.
In all male dose groups the absolute and relative liver weights were higher compared to the control. In females, significantly higher relative liver weights were recorded in the Mid and High dose groups.
Weight findings in other organs were considered incidental and not test substance related.
see Table on kidney and liver weights attached as background material - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Test item-related findings were seen in the liver and kidneys of the following animals:
Low dose group (30 mg/kg bw/day): Minimal hepatocellular hypertrophy in the centrilobular zone of the liver in 2/12 males.
Mid dose group (100 mg/kg bw/day): Minimal hepatocellular hypertrophy in the centrilobular zone of the liver in 11/12 males and 12/12 females, minimal eosinophilic droplets in the tubular section of the kidneys in 5/12 males.
High dose group (300 mg/kg bw/day): Slight to moderate hepatocellular hypertrophy in the centrilobular zone of the liver in 1/12 males and 7/12 females, slight hepatocellular microvesicular vacuolation in the centrilobular zone of the liver in 2/12 males and 1/12 females, moderate hepatocellular degeneration in the centrilobular and periportal zones of the liver in 5/12 males and 4/12 females, moderate multifocal macrovesicular inflammatory cell infiltration with hepatocellular apoptosis in the liver in 1/12 male, minimal to marked eosinophilic droplets in the tubular section of the kidneys in 9/12 males.
Hepatocellular degeneration was considered as adverse change (seen only in High dose animals), while hypertrophy was considered to be non-adverse adaptive change (seen in Low dose males and Mid and High dose of both sexes). Vacuolation (seen in two High dose males and one High dose female and also in the found dead High dose female) was also regarded as non-adverse.
In the kidneys of 5/12 Mid dose and 9/12 High dose males minimal/marked eosinophilic droplets were seen, correlated with organ weight changes. This was regarded as non-adverse.
Other observations in the kidneys were of low incidence and/or severity and/or distributed across control and dosed animals. They were considered incidental or a common background. - Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 100 - < 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- System:
- hepatobiliary
- Organ:
- liver
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the NOAEL of 100 mg/kg body weight/d and the liver effects observed at the dose level of 300 mg/kg body weight/day in the sub-acute repeated dose oral toxicity study WS400304 has to be classified STOT RE 2.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)